Angel Ramos Macías1, Juan Carlos Falcón-González1, Manuel Manrique Rodríguez2, Constantino Morera Pérez3, Luis García-Ibáñez4, Carlos Cenjor Español5, Chrystelle Coudert-Koall6, Matthijs Killian6. 1. Unidad de Hipoacusia, Servicio de Otorrinolaringología, Complejo Hospitalario Universitario Insular Materno Infantil, Las Palmas, Spain. 2. Servicio de Otorrinolaringología, Clínica Universitaria de Navarra, Pamplona, Spain. 3. Servicio de Otorrinolaringología, Hospital Universitario La Fe, Valencia, Spain. 4. Servicio de Otorrinolaringología, Instituto de Otologia Garcia Ibanez, Barcelona, Spain. 5. Servicio de Otorrinolaringología, Fundacion Jimenez Diaz, Madrid, Spain. 6. Cochlear EMEA, Basel, Switzerland.
Abstract
OBJECTIVE: To show that patients with unilateral hearing loss (UHL), with one ear fulfilling cochlear implant (CI) indication criteria, and an additional severe tinnitus handicap can be treated effectively with a CI. METHOD: A prospective multi-centre study was conducted in five Spanish centres. Sixteen adult patients with UHL and a mean Tinnitus Handicap Inventory (THI) score of at least 58 were implanted. The study design included repeated within-subject measures of quality of life (Health Utility Index Mark 3 [HUI3]), tinnitus (THI, Visual Analogue Scale [VAS] on tinnitus loudness), hearing (Speech, Spatial, and Qualities of Hearing Scale- [SSQ]), and hyperacusis (Test de Hipersensibilidad al Sonido [THS]) up to 12 months after the initial CI fitting. RESULTS: Group data showed significant subjective benefit from CI treatment: the preoperative HUI3 total utility score of 0.45 went up to 0.57 at 6 months and 0.63 at 12 months; the preoperative THI total score of 75 decreased to 40 at 6 months and 35 at 12 months. The preoperative tinnitus loudness VAS score of 8.2 decreased to 2.4 at 6 months and 2.2 at 12 months with the implant "On" and to 6.7 at 6 months and 6.5 at 12 months with the implant "Off." The preoperative THS total score of 26 decreased to 17 at 12 months. The preoperative SSQ total score of 4.2 increased to 5.1 at 6 months and 6.3 at 12 months. No unanticipated adverse events were reported during the study period. At 12 months after CI activation all subjects (except 1 subject who used the device 6 days a week) wore their devices all day and every day. The primary reason for CI use was split evenly between tinnitus suppression (n = 6) and both hearing and tinnitus (n = 6). CONCLUSION: A CI should be considered as a treatment option in patients with UHL and a concomitant severe tinnitus handicap. However, appropriate counselling of candidates on the anticipated risks, benefits, and limitations that are inherent to cochlear implantation is imperative.
OBJECTIVE: To show that patients with unilateral hearing loss (UHL), with one ear fulfilling cochlear implant (CI) indication criteria, and an additional severe tinnitus handicap can be treated effectively with a CI. METHOD: A prospective multi-centre study was conducted in five Spanish centres. Sixteen adult patients with UHL and a mean Tinnitus Handicap Inventory (THI) score of at least 58 were implanted. The study design included repeated within-subject measures of quality of life (Health Utility Index Mark 3 [HUI3]), tinnitus (THI, Visual Analogue Scale [VAS] on tinnitus loudness), hearing (Speech, Spatial, and Qualities of Hearing Scale- [SSQ]), and hyperacusis (Test de Hipersensibilidad al Sonido [THS]) up to 12 months after the initial CI fitting. RESULTS: Group data showed significant subjective benefit from CI treatment: the preoperative HUI3 total utility score of 0.45 went up to 0.57 at 6 months and 0.63 at 12 months; the preoperative THI total score of 75 decreased to 40 at 6 months and 35 at 12 months. The preoperative tinnitus loudness VAS score of 8.2 decreased to 2.4 at 6 months and 2.2 at 12 months with the implant "On" and to 6.7 at 6 months and 6.5 at 12 months with the implant "Off." The preoperative THS total score of 26 decreased to 17 at 12 months. The preoperative SSQ total score of 4.2 increased to 5.1 at 6 months and 6.3 at 12 months. No unanticipated adverse events were reported during the study period. At 12 months after CI activation all subjects (except 1 subject who used the device 6 days a week) wore their devices all day and every day. The primary reason for CI use was split evenly between tinnitus suppression (n = 6) and both hearing and tinnitus (n = 6). CONCLUSION: A CI should be considered as a treatment option in patients with UHL and a concomitant severe tinnitus handicap. However, appropriate counselling of candidates on the anticipated risks, benefits, and limitations that are inherent to cochlear implantation is imperative.
Authors: Margaret T Dillon; Emily Buss; Meredith L Anderson; English R King; Ellen J Deres; Craig A Buchman; Kevin D Brown; Harold C Pillsbury Journal: Ear Hear Date: 2017 Sep/Oct Impact factor: 3.570
Authors: Tao Pan; Richard S Tyler; Haihong Ji; Claudia Coelho; Anne K Gehringer; Stephanie A Gogel Journal: Am J Audiol Date: 2009-12 Impact factor: 1.493
Authors: Jeroen Pm Peters; Alice van Zon; Adriana L Smit; Gijsbert A van Zanten; G Ardine de Wit; Inge Stegeman; Wilko Grolman Journal: BMC Ear Nose Throat Disord Date: 2015-05-23
Authors: Richard Salvi; Wei Sun; Dalian Ding; Guang-Di Chen; Edward Lobarinas; Jian Wang; Kelly Radziwon; Benjamin D Auerbach Journal: Front Neurosci Date: 2017-01-18 Impact factor: 4.677
Authors: Kelly Assouly; Adriana L Smit; Inge Stegeman; Koenraad S Rhebergen; Bas van Dijk; Robert Stokroos Journal: BMJ Open Date: 2021-05-18 Impact factor: 3.006
Authors: Andrew J Redmann; Kareem Tawfik; Theresa Hammer; Lisa Wenstrup; Shawn Stevens; Joseph T Breen; Ravi N Samy Journal: Laryngoscope Investig Otolaryngol Date: 2021-03-26
Authors: Samar A Idriss; Pierre Reynard; Mathieu Marx; Albane Mainguy; Charles-Alexandre Joly; Eugen Constant Ionescu; Kelly K S Assouly; Hung Thai-Van Journal: J Clin Med Date: 2022-09-26 Impact factor: 4.964
Authors: Luis Lassaletta; Miryam Calvino; Isabel Sanchez-Cuadrado; Piotr Henryk Skarzynski; Katarzyna B Cywka; Natalia Czajka; Justyna Kutyba; Dayse Tavora-Vieira; Paul van de Heyning; Griet Mertens; Hinrich Staecker; Bryan Humphrey; Mario Zernotti; Maximo Zernotti; Astrid Magele; Marlene Ploder; Julia Speranza Zabeu Journal: Int J Environ Res Public Health Date: 2022-02-22 Impact factor: 3.390